We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.53B
1-Year Est. Return 154.61%
This Fund
S&P 500
This Quarter Est. Return
-11.79%
1 Year Est. Return
+154.61%
3 Year Est. Return
+564.07%
5 Year Est. Return
+985.88%
10 Year Est. Return
–
AUM
$227M
AUM Growth
-$29.8M
Cap. Flow
+$4.07M
Cap. Flow %
1.79%
Top 10 Hldgs %
39.83%
Holding
81
New
31
Increased
12
Reduced
7
Closed
30

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$10.7M
2
AZN icon
AstraZeneca
AZN
+$8.94M
3
EHC icon
Encompass Health
EHC
+$8.33M
4
CTLT
CATALENT, INC.
CTLT
+$8.19M
5
DHR icon
Danaher
DHR
+$7.6M

Top Sells

Rank Stock Value
1
A icon
Agilent Technologies
A
+$14.5M
2
DXCM icon
DexCom
DXCM
+$13.1M
3
AMED
Amedisys
AMED
+$10.8M
4
SNY icon
Sanofi
SNY
+$9.54M
5
VAR
Varian Medical Systems, Inc.
VAR
+$8.52M

Sector Composition

Rank Sector Weight
1 Healthcare 93.4%
2 Energy 3.09%
3 Miscellaneous 1.86%
4 Consumer Discretionary 1.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WBA
26
DELISTED
Walgreens Boots Alliance
WBA
$3.66M 1.61%
+80,000
New +$4.06M
ABT icon
27
Abbott
ABT
$175B
$3.55M 1.56%
+45,000
New +$3.75M
BPMC
28
DELISTED
Blueprint Medicines
BPMC
$3.51M 1.55%
60,000
+40,000
+200% +$2.57M
ISRG icon
29
Intuitive Surgical
ISRG
$143B
$3.47M 1.53%
+21,000
New +$3.85M
DRNA
30
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.4M 1.5%
185,000
-15,000
-8% -$292K
RVTY icon
31
Revvity
RVTY
$16.9B
$3.39M 1.49%
+45,000
New +$3.99M
MCK icon
32
McKesson
MCK
$101B
$3.38M 1.49%
+25,000
New +$3.66M
NVO
33
Novo Nordisk
NVO
$171B
$3.31M 1.46%
110,000
+30,000
+38% +$893K
MRTX
34
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.08M 1.35%
40,000
+25,000
+167% +$2.24M
EXEL icon
35
Exelixis
EXEL
$14.4B
$2.58M 1.14%
+150,000
New +$2.74M
UNH icon
36
UnitedHealth
UNH
$338B
$2.49M 1.1%
+10,000
New +$2.75M
TXG icon
37
10x Genomics
TXG
$11.2B
$2.49M 1.1%
40,000
+15,000
+60% +$1.17M
ALKS icon
38
Alkermes
ALKS
$6.85B
$2.16M 0.95%
+150,000
New +$2.68M
FATE icon
39
Fate Therapeutics
FATE
$282M
$2.11M 0.93%
+95,000
New +$2.4M
KPTI icon
40
Karyopharm Therapeutics
KPTI
$36.7M
$1.92M 0.85%
6,667
-16,333
-71% -$4.51M
EXEL icon
41
CALL
Exelixis
EXEL
$14.4B
$1.72M 0.76%
+100,000
New +$1.83M
BMY.RT
42
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$1.71M 0.75%
450,000
-100,000
-18% -$329K
ARVN icon
43
Arvinas
ARVN
$496M
$1.61M 0.71%
+40,000
New +$1.87M
DNLI icon
44
Denali Therapeutics
DNLI
$3.26B
$1.58M 0.69%
+90,000
New +$1.88M
HUM icon
45
Humana
HUM
$47.8B
$1.57M 0.69%
5,000
-18,000
-78% -$6.07M
AKBA icon
46
Akebia Therapeutics
AKBA
$248M
$1.52M 0.67%
+200,000
New +$1.56M
NERV icon
47
Minerva Neurosciences
NERV
$162M
$1.5M 0.66%
31,250
+8,750
+39% +$528K
AKRO
48
DELISTED
Akero Therapeutics
AKRO
$1.27M 0.56%
+60,000
New +$1.29M
HALO icon
49
Halozyme
HALO
$12.9B
$900K 0.4%
+50,000
New +$949K
AMRN
50
CALL
Amarin Corp
AMRN
$279M
$800K 0.35%
+10,000
New +$3.32M
1
2
3 4

Similar funds

VWA
Visionary Wealth Advisors O'fallon, Illinois $2.53B AUM 24.4% 1-Year Est. Return
PVI
Pine Valley Investments Marlton, New Jersey $2.53B AUM 36.18% 1-Year Est. Return
AIM
Acropolis Investment Management St. Louis, Missouri $2.54B AUM 18.96% 1-Year Est. Return
QT
Quantbot Technologies New York $2.54B AUM 22.25% 1-Year Est. Return
LMIM
Lockheed Martin Investment Management Bethesda, Maryland $2.53B AUM 37.62% 1-Year Est. Return
ST
Sageworth Trust Lancaster, Pennsylvania $2.54B AUM 23.56% 1-Year Est. Return
NSAM
North Star Asset Management Neenah, Wisconsin $2.54B AUM 17.62% 1-Year Est. Return
IFA
Index Fund Advisors Irvine, California $2.52B AUM 26.26% 1-Year Est. Return

Integral Health Asset Management's Q1 2020 Portfolio in Review

As of Q1 2020, Integral Health Asset Management held 81 positions worth $227M, down 12% from $257M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Integral Health Asset Management's Q1 2020 filing shows 31 new, 12 increased, 7 reduced and 30 closed positions. Its largest new stake was Merck: 136,240 shares worth $10M. The largest sale was Agilent Technologies, an estimated $14.5M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 99% a quarter earlier, followed by Energy and Miscellaneous.

  • Integral Health Asset Management's largest Q1 2020 buy was Merck: 136,240 shares worth $10M.
  • Integral Health Asset Management added most to ChemoCentryx, Inc. in Q1 2020, an estimated $5.94M increase.
  • Integral Health Asset Management's biggest Q1 2020 reduction was Humana, cutting an estimated $6.07M.
  • Integral Health Asset Management fully exited Agilent Technologies in Q1 2020, selling an estimated $14.5M.
  • Integral Health Asset Management's ten largest holdings make up 40% of its $227M portfolio in Q1 2020.
  • Integral Health Asset Management opened 31 new positions and closed 30 in Q1 2020.
  • Integral Health Asset Management's portfolio value fell 12% quarter-over-quarter to $227M.

Based on Integral Health Asset Management's 13F filing for Q1 2020, filed 15 May 2020.